Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US81663L2007
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG00XDHY5P9
WGS
GeneDx Holdings Corp
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $GRLZ
NAME
GeneDx Holdings Corp
ISIN
US81663L2007
TICKER
WGS
MIC
XNAS
REUTERS
WGS.OQ
BLOOMBERG
WGS US
Fr., 12.06.2026       GeneDx
US81663L2007

New York, New York--(Newsfile Corp. - June 11, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you w...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Fr., 12.06.2026       GeneDx
US81663L2007

NEW YORK, June 11, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against GeneDx Holdings Corp. ("GeneDx" or the "Company") (NASDAQ: WGS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are e...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Do., 11.06.2026       GeneDx
US81663L2007

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In GeneDx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in GeneDx between April 16, 2025 and May 4, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wils...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Do., 11.06.2026       GeneDx
US81663L2007

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - June 11, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until August 3, 2026 to file lead plaintiff applications in a securities class action lawsuit agains...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Do., 11.06.2026       GeneDx
US81663L2007

LOS ANGELES, June 11, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ: WGS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U....
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Do., 11.06.2026       GeneDx
US81663L2007

New York, New York--(Newsfile Corp. - June 11, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violations...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Do., 11.06.2026       GeneDx
US81663L2007

SAN FRANCISCO, June 11, 2026 /PRNewswire/ -- GeneDx Holdings (NASDAQ: WGS) faces a securities class action after the price of the company's stock cratered $33.42 (-49%) on May 5, 2026 in response to the company's disastrous Q1 2026 earnings report. The lawsuit seeks to represent investors who purchased shares of GeneDx common stock between April 1...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Do., 11.06.2026       GeneDx
US81663L2007

Key Dates and Disclosure Events GeneDx Shareholders Need to Know: From $51 Million Acquisition Promise to $31.2 Million Write-Off in Just 12 MonthsNEW YORK, June 11, 2026 /PRNewswire/ -- April 16, 2025. May 5, 2025. July 29, 2025. October 28, 2025. February 23, 2026. May 4, 2026. Between these dates, GeneDx Holdings Corp. (NASDAQ: WGS) shareholder...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Do., 11.06.2026       GeneDx
US81663L2007

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025 and May 4, 2026, both dates inclusive (the “Class Period”), have until August 3, 2026 to seek appointment as lead plaintiff of the GeneDx class action lawsuit. Captioned Basma v. GeneDx Holdings...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Do., 11.06.2026       GeneDx
US81663L2007

New York, New York--(Newsfile Corp. - June 10, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you w...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mi., 10.06.2026       GeneDx
US81663L2007

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - June 10, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until August 3, 2026 to file lead plaintiff applications in a securities class action lawsuit agains...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Mi., 10.06.2026       GeneDx
US81663L2007

Time-Sensitive: Allegations Focus on Deteriorating Reimbursement Rates and Margin Compression Concealed From GeneDx InvestorsNEW YORK, June 10, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP alerts investors in GeneDx Holdings Corp. (NASDAQ: WGS) of a pending securities class action. Class Period: April 16, 2025 through May 4, 2026. Check if you c...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Mi., 10.06.2026       GeneDx
US81663L2007

Philadelphia, Pennsylvania--(Newsfile Corp. - June 10, 2026) - WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.If you purchased GeneDx Holdings Corp....
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Mi., 10.06.2026       GeneDx
US81663L2007

New York, New York--(Newsfile Corp. - June 9, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wi...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Di., 09.06.2026       GeneDx
US81663L2007

Levi & Korsinsky, LLP highlights the contrast between GeneDx Holdings Corp.'s (NASDAQ: WGS) promises to investors and the actual results of its Fabric Genomics acquisition. Shareholders who purchased WGS securities between April 16, 2025 and May 4, 2026 and suffered losses may be entitled to compensation. Find out if you can recover your invest...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Di., 09.06.2026       GeneDx
US81663L2007

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - June 9, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until August 3, 2026 to file lead plaintiff applications in a securities class action lawsuit against...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Di., 09.06.2026       GeneDx
US81663L2007

New York, New York--(Newsfile Corp. - June 9, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violations o...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Di., 09.06.2026       GeneDx
US81663L2007

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In GeneDx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in GeneDx between April 16, 2025 and May 4, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wils...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Di., 09.06.2026       GeneDx
US81663L2007

SAN FRANCISCO, June 9, 2026 /PRNewswire/ -- GeneDx Holdings (NASDAQ: WGS) faces a securities class action after the price of the company's stock cratered $33.42 (-49%) on May 5, 2026 in response to the company's disastrous Q1 2026 earnings report. The lawsuit seeks to represent investors who purchased shares of GeneDx common stock between April 16...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Di., 09.06.2026       GeneDx
US81663L2007

NEW YORK, June 9, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of GeneDx Holdings Corp. (NASDAQ: WGS). Shareholders who purchased shares of WGS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff a...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Di., 09.06.2026       GeneDx
US81663L2007

SAN DIEGO, June 8, 2026 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025 and May 4, 2026. GeneDx Holdings Corp is a genomics company that provides genetic testing services for diagnosi...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Di., 09.06.2026       GeneDx
US81663L2007

New York, New York--(Newsfile Corp. - June 8, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wi...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Di., 09.06.2026       GeneDx
US81663L2007

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until August 3, 2026 to file lead plaintiff applications in a securities class action lawsuit against GeneDx Holdings Corp. (NasdaqGS: WGS) (“GeneDx” or the “Company”), if they purc...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Mo., 08.06.2026       GeneDx
US81663L2007

LOS ANGELES, June 8, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ: WGS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
So., 07.06.2026       GeneDx
US81663L2007

NEW YORK, June 7, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) and certain of its officers....
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
So., 07.06.2026       GeneDx
US81663L2007

New York, New York--(Newsfile Corp. - June 7, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wi...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Sa., 06.06.2026       GeneDx
US81663L2007

NEW YORK, June 6, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive (the "Class Period"). A cla...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Sa., 06.06.2026       GeneDx
US81663L2007

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In GeneDx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in GeneDx between April 16, 2025 and May 4, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wils...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Sa., 06.06.2026       GeneDx
US81663L2007

New York, New York--(Newsfile Corp. - June 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wi...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Sa., 06.06.2026       GeneDx
US81663L2007

Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026. GeneDx describes itself as an “American biotechnology company specializing in genomic diagnostics, with a focus on whole genome sequencing and whol...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Fr., 05.06.2026       GeneDx
US81663L2007

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GeneDx Holdings Corp. (“GeneDx” or “the Company”) (NASDAQ: WGS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. In...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Fr., 05.06.2026       GeneDx
US81663L2007

New York, New York--(Newsfile Corp. - June 5, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violations o...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Fr., 05.06.2026       GeneDx
US81663L2007

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In GeneDx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in GeneDx between April 16, 2025 and May 4, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wils...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Fr., 05.06.2026       GeneDx
US81663L2007

SAN FRANCISCO, June 5, 2026 /PRNewswire/ -- GeneDx Holdings (NASDAQ: WGS) faces a securities class action after the price of the company's stock cratered $33.42 (-49%) on May 5, 2026 in response to the company's disastrous Q1 2026 earnings report. The lawsuit seeks to represent investors who purchased shares of GeneDx common stock between April 16...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Fr., 05.06.2026       GeneDx
US81663L2007

SAN DIEGO, June 4, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers of GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025 and May 4, 2026, inclusive (the "Class Period"), have until August 3, 2026 to seek appointment as lead plaintiff of the GeneDx class action lawsuit. Captioned Basma v. Gen...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Do., 04.06.2026       GeneDx
US81663L2007

Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025 and May 4, 2026. GeneDx Holdings Corp is a genomics company that provides genetic testing services for diagnosing pediatric and rare diseases. For mo...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Do., 04.06.2026       GeneDx
US81663L2007

SAN FRANCISCO, June 4, 2026 /PRNewswire/ -- Investors in GeneDx Holdings Corp. (NASDAQ: WGS) saw the price of their shares tank $33.42 (-49%) on May 5, 2025 after the company announced a massive Q1 2026 earnings miss, a tenfold increase in net loss, and a drastic reduction in full-year 2026 guidance. The stock's move lower wiped out over $900 mill...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Do., 04.06.2026       GeneDx
US81663L2007

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS) and reminds investors of the August 3, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.This press re...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Do., 28.05.2026       GeneDx
US81663L2007

SAN FRANCISCO, May 28, 2026 /PRNewswire/ -- Investors in GeneDx Holdings Corp. (NASDAQ: WGS) saw the price of their shares tank $33.42 (-49%) on May 5, 2025 after the company announced a massive Q1 2026 earnings miss, a tenfold increase in net loss, and a drastic reduction in full-year 2026 guidance. The stock's move lower wiped out over $900 mill...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Di., 26.05.2026       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that company management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference from June 8-10 in Miami, FL. Management will participate in a fireside chat on Tuesday, June 9, 2026, at 8:00 a.m....
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Do., 21.05.2026       GeneDx
US81663L2007

NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp.  ("GeneDx" or the "Company") (NASDAQ: WGS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Mi., 20.05.2026       GeneDx
US81663L2007

GeneDx posted Q1 2026 revenue of $102.3 million against consensus estimates near $110 million and reported adjusted EPS of -$0.28 versus the -$0.01 expected -- the stock collapsed approximately 44% in a single session. NEW YORK, May 20, 2026 /PRNewswire/ -- Shareholders who held GeneDx Holdings Corp. (NASDAQ: WGS) stock lost approximately 44% of...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Mo., 18.05.2026       GeneDx
US81663L2007

New York, New York--(Newsfile Corp. - May 18, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into GeneDx Holdings Corp. (NASDAQ: WGS) ("GeneDx Holdings Corp.") concerning potential violations of the federal securities laws.On its Q4 2025 earnings call on February 23, 2026, CFO Kevin Feeley told investors...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Fr., 15.05.2026       GeneDx
US81663L2007

NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp.  ("GeneDx" or the "Company") (NASDAQ: WGS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Mi., 13.05.2026       GeneDx
US81663L2007

GeneDx CFO promised quarterly profitability weeks before the company posted an $8.2 million adjusted loss -- and then cut full-year guidance by approximately 12%. NEW YORK, May 13, 2026 /PRNewswire/ -- Investors in GeneDx Holdings Corp. (NASDAQ: WGS) lost approximately 44% of their share value after Q1 2026 earnings revealed a significant revenue...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Mo., 11.05.2026       GeneDx
US81663L2007

Boston, Massachusetts--(Newsfile Corp. - May 11, 2026) - Block & Leviton is investigating GeneDX Holdings Corp. (NASDAQ: WGS) for potential securities law violations. Investors who have lost money in their GeneDX Holdings Corp. investment should contact the firm to learn more about how they might recover those losses. For more details, visit ht...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Mo., 11.05.2026       GeneDx
US81663L2007

New York, New York--(Newsfile Corp. - May 11, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into GeneDx Holdings Corp. ("GeneDx Holdings Corp.") (NASDAQ: WGS) concerning potential violations of the federal securities laws.On its Q4 2025 earnings call on February 23, 2026, CFO Kevin Feeley told investors the...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Fr., 08.05.2026       GeneDx
US81663L2007

NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp.  ("GeneDx" or the "Company") (NASDAQ: WGS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Do., 07.05.2026       GeneDx
US81663L2007

New York, New York--(Newsfile Corp. - May 7, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into GeneDx Holdings Corp. ("GeneDx Holdings Corp.") (NASDAQ: WGS) concerning potential violations of the federal securities laws.On its Q4 2025 earnings call on February 23, 2026, CFO Kevin Feeley told investors the c...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Do., 07.05.2026       GeneDx
US81663L2007

The law firm of Kirby McInerney LLP is investigating potential claims against GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ:WGS). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVES...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink